| Biomarker ID | 702 |
| PMID | 21822036 |
| Year | 2011 |
| Biomarker | Methylation Status of (RARB or GSTP1 or RASSF1) |
| Biomarker Basis | Methylation Based |
| Biomolecule | Methylation |
| Source | Urine |
| Subjects | Humans |
| Regulation | Hypermethylated in Cancer |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways include (GSTP1): Biological oxidations, Metapathway biotransformation, Pathways in cancer, T cell receptor regulation of apoptosis, Metabolism Pathways Include(RARB):-Non-small cell lung cancer,Vitamin A and carotenoid metabolism,Nuclear receptor transcription pathway,Nuclear receptors,Small cell lung cancer Pathways Include(RASSF1):- Bladder cancer, Non-small cell lung cancer, p53 activity regulation, Pathways in cancer |
| Experiment | Methylation in Patients with PCa |
| Type of Biomarker | Prognostic |
| Cohort | 34 patients with untreated prostate cacner were selected, The cases were diagnosed with early- (pT2, n=21) or medium-stage (pT3, n=13) prostate carcinoma of score 6 (n=24) or 7 (n=10). |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | 82% |
| Level Of Significance | NA |
| Method Used | Real-time methylation-specific PCR |
| Clinical | No |
| Remarks | The frequencies of aberrant promoter methylation for RASSF1, RARB, and GSTP1 were 71% (24 of 34), 44% (15 of 34), and 3% (1 of 34), respectively. |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | RARB, GSTP1, RASSF1 |